US20070116647A1 - Medicinal preparation particularly for the treatment of slipped discs hernias - Google Patents

Medicinal preparation particularly for the treatment of slipped discs hernias Download PDF

Info

Publication number
US20070116647A1
US20070116647A1 US10/513,592 US51359203A US2007116647A1 US 20070116647 A1 US20070116647 A1 US 20070116647A1 US 51359203 A US51359203 A US 51359203A US 2007116647 A1 US2007116647 A1 US 2007116647A1
Authority
US
United States
Prior art keywords
preparation
ethanol
compound
treatment
ethylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/513,592
Inventor
Jacques Theron
Marc d'Aboville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20070116647A1 publication Critical patent/US20070116647A1/en
Assigned to THERON, JACQUES reassignment THERON, JACQUES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: D'ABOVILLE, COME PHILIPPE GUY (ON BEHALF OF MARC D'ABOVILLE, DECEASED), D'ABOVILLE, CHRISTINE MARIE JOSEPH (ON BEHALF OF MARC D'ABOVILLE (DECEASED), D'ABOVILLE, CHRISTINE MARIE JOSEPH (ON BEHALF OF MICHEL SEVERIN D'ABOVILLE, A MINOR, ON BEHALF OF MARC D'ABOVILLE, DECEASED), D'ABOVILLE, QUENTIN BRUNNO PIERRE (ON BEHALF OF MARC D'ABOVILLE, DECEASED), D'ABOVILLE, SOLINE ALIX MARIE (ON BEHALF OF MARC D'ABOVILLE, DECEASED)
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention concerns a viscous injectable medicinal preparation containing ethanol and a compound opaque to X-rays.
  • Discal hernias are the main causes of back pains and sciaticas. They are usually related to multiple ergonomic and anatomic factors such as poor posture, abdominal and paraspinal muscle weakness, etc.
  • nucleolysis enzymatic alteration of an intervertebral disc
  • absolute alcohol anhydrous ethanol
  • sclerosis of the ganglia and nerves has been used as an effective therapeutic agent in many interventional procedures such as sclerosis of the ganglia and nerves; ablation of liver tumours and kidney tumours; preoperative treatment for vertebral tumours; arteriovenous, peripheral, visceral and brain malformations, etc.
  • the use of alcohol in the treatment of hepato-cellular tumours can cause thrombosis of the portal vein by diffusion of the product into the venous system.
  • One of the applicant's objectives is to avoid the side effects of ethanol in this disorder, in other words necrosis of healthy tissues which occurs as a result of diffusion at a distance from the target as well as to reinforce effectiveness.
  • an injectable medicinal preparation which comprises at least one compound used to make the preparation viscous, ethanol and at least one compound making said preparation opaque to X-rays in order to manage its administration and action.
  • viscosity limits diffusion of the preparation to a specific area and reinforces its therapeutic effect.
  • This preparation thus has the dual advantage of offering an active principle with limited diffusion and a marker to be able to better monitor injection as the therapist performs the procedure and, most importantly, for post-treatment monitoring of the exact location of the injected product with the aid of a scanner.
  • the compounds used to make the preparation opaque to X-rays can be inert compounds such as tungsten oxide or tantalum oxide.
  • These compounds can be added for example in powder form either at the end of the preparation manufacturing process or immediately prior to injection.
  • Ethylcellulose was selected as the compound (excipient) used to achieve the required viscosity. This choice is based on several criteria:
  • the preparation according to the invention fulfils the required criteria which are safety of use in all phases of the process and the ability to produce stable and selective sclerosis.
  • FIG. 1 represents measurement of viscosity expressed in pharmaceutical units as a function of concentration given as the percentage of ethylcellulose weight with respect to total weight;
  • FIG. 2 represents measurement of viscosity expressed in pharmaceutical units as a function of temperature given in degrees Celsius.
  • ethylcellulose is used at a concentration ranging from 0.5 to 15%, preferably 5.88%, by weight of the preparation's total weight.
  • the preparation was manufactured in three stages: gel preparation, aseptic distribution and sterilisation of the product in the final packaging.
  • the excipient ethylcellulose
  • the mixture was stirred and refluxed for 15 minutes then stirred until it cooled down completely in order to allow recondensation of the alcohol in the flask. It was then packaged under a horizontal laminar flux hood into 5 mL sterile bottles (bioblock 42065).
  • the bottles were sterilised in a autoclave using saturated vapour at 121° C. for 20 minutes.
  • the final step in the manufacturing process of the preparation is the addition of a powdered opacifying compound such as tantalum oxide or tungsten oxide in varying proportions so as to obtain good opacity.
  • a powdered opacifying compound such as tantalum oxide or tungsten oxide in varying proportions so as to obtain good opacity. This addition can take place either at the end of the manufacturing process prior to packaging or just before carrying out the injection.
  • the conformity of the preparation was verified by means of a sterility test and chemical and physico-chemical tests.
  • Alcohol content was determined after dilution of a sample and incorporation of the internal standard, propanol-1, by gas chromatography with detection by flame ionisation. Separation was by means of a Porapak Q column (80-100 mesh, length 3 m) with nitrogen as the carrier gas (1.2 bar) on a Delsi DN200 apparatus. The alcohol assay gave a value of 802 g.L ⁇ 1 .
  • the specific assay for the viscosity additive was not performed but the concentration was estimated by means of the dry residues method, a process which consists in evaporating ethanol in a tank whose temperature was maintained at 110° C. until the sample reached constant weight.
  • the dry residues method allowed a correlation to be made between the theoretical ethylcellulose concentration and the experimentally measured concentration, that is 5.88% by weight of the sample's total weight.
  • the viscosity of the preparation was measured by means of a Baumé capillary viscosimeter (Prolabo). Several series of measurements were performed at different temperatures and different concentrations of the thickener. The viscosity measurements showed that, at constant temperature, the preparation increased exponentially as a function of ethylcellulose content ( FIG. 1 ). However, it decreased, also exponentially, when the temperature increased ( FIG. 2 ).

Abstract

The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.

Description

  • The invention concerns a viscous injectable medicinal preparation containing ethanol and a compound opaque to X-rays.
  • It is more particularly but not exclusively applicable to the treatment of discal hernias as well as to interventional procedures where pure ethanol has been found to be effective: treatment of hepato-cellular tumours or osteoid osteomas, kidney cysts and arteriovenous angiomas.
  • Discal hernias are the main causes of back pains and sciaticas. They are usually related to multiple ergonomic and anatomic factors such as poor posture, abdominal and paraspinal muscle weakness, etc.
  • Traditional and surgical therapies are the treatment of choice in most cases. However, for certain patients with well-defined clinical and radiological criteria a percutaneous treatment can be offered.
  • The efficacy of percutaneous treatment for lumbar discal hernias by injection of an enzyme, chymopapain (nucleolysis: enzymatic alteration of an intervertebral disc), is well established. Nevertheless, patients with a history of allergy or those have already received nucleolysis treatment can not take advantage of this procedure.
  • With regard to the necrosing effect of ethanol on biological tissues absolute alcohol (anhydrous ethanol) has been used as an effective therapeutic agent in many interventional procedures such as sclerosis of the ganglia and nerves; ablation of liver tumours and kidney tumours; preoperative treatment for vertebral tumours; arteriovenous, peripheral, visceral and brain malformations, etc.
  • One team recently considered the use of these therapeutic properties in the treatment of back disorders. They treated lumbar discal hernias with intradiscal injections of absolute alcohol with very promising results. This percutaneous procedure has a number of advantages:
      • no allergic complication,
      • no local septic complication,
      • less post-treatment pain,
      • no shrinkage of the interdiscal space,
      • no inflammatory complication,
      • a shorter clinical recovery time.
  • Nonetheless, ethanol, because of its properties, can diffuse at a distance from its target and cause necrosis of healthy cells. This is why the team using pure ethanol contraindicated its use for discal hernias with epidural leakage as revealed by discography as well as in cases of cervical discal hernias.
  • Moreover, the use of alcohol in the treatment of hepato-cellular tumours can cause thrombosis of the portal vein by diffusion of the product into the venous system. One of the applicant's objectives is to avoid the side effects of ethanol in this disorder, in other words necrosis of healthy tissues which occurs as a result of diffusion at a distance from the target as well as to reinforce effectiveness.
  • To this end, the applicant has tested several thickeners and is proposing an injectable medicinal preparation which comprises at least one compound used to make the preparation viscous, ethanol and at least one compound making said preparation opaque to X-rays in order to manage its administration and action.
  • Advantageously, viscosity limits diffusion of the preparation to a specific area and reinforces its therapeutic effect.
  • This preparation thus has the dual advantage of offering an active principle with limited diffusion and a marker to be able to better monitor injection as the therapist performs the procedure and, most importantly, for post-treatment monitoring of the exact location of the injected product with the aid of a scanner.
  • The compounds used to make the preparation opaque to X-rays can be inert compounds such as tungsten oxide or tantalum oxide.
  • These compounds can be added for example in powder form either at the end of the preparation manufacturing process or immediately prior to injection.
  • Ethylcellulose was selected as the compound (excipient) used to achieve the required viscosity. This choice is based on several criteria:
      • its hydrophilic nature, given the fact that the preparation is for injection,
      • its thickening capacity which has to be sufficient, even when present in small amounts, to increase the mixture's viscosity,
      • cellulose derivatives are water-soluble in vitro and therefore circumvent the need for surgical resection of the treated area,
      • it is in the form of a powder and not a liquid in order not to dilute the ethanol,
      • a certain degree of solubility in ethanol so as to obtain a homogeneous preparation,
      • systemic and/or local toxic effects reduced to a minimum, and preferably non-existent, in order not to compromise tolerance to the preparation.
  • Consequently, the preparation according to the invention fulfils the required criteria which are safety of use in all phases of the process and the ability to produce stable and selective sclerosis.
  • One mode of implementation of the invention, given as a non-limiting, example, will be described hereinafter:
  • FIG. 1 represents measurement of viscosity expressed in pharmaceutical units as a function of concentration given as the percentage of ethylcellulose weight with respect to total weight;
  • FIG. 2 represents measurement of viscosity expressed in pharmaceutical units as a function of temperature given in degrees Celsius.
    • CHOICE OF EXCIPIENTS USED IN THE PREPARATION
  • Six products registered in the European Pharmacopoeia 3rd edition (1999) and fulfilling the above-mentioned criteria were chosen for evaluation as an excipient (Table I). Each of these was tested for solubility in hot/cold ethanol. In addition, the physico-chemical compatibility of substances in contact with each other (by visual evaluation) and the approximate viscosity of the mixture were also examined.
    TABLE I
    Products tested for gel manufacture
    Products Commercial references Suppliers
    Hydroxycellulose Klucel MF EP ® Aldrich
    Klucel HF EP ®
    Ethylcellulose Aqualon 100 NF ® Hercules
    Polysorbate Montanox 80 ® Seppic
    Colloidal Silica Aérosil R972 ® Degussa France
    Aérosil R200 ®
    Carboxypolymethylene Carbopol 940 ® Gattefosse
    Carbopol 934 ®
    Polyethyleneglycol Lutrol E4000 ® BASF France
    Lutrol E6000 ®
  • The results of various tests are summarized in Table II. All the products tested were soluble in hot ethanol. Only ethylcellulose was also more or less soluble in cold ethanol. Moreover, the physico-chemical compatibility of the mixture (absence of precipitation) was good and viscosity was satisfactory. This is why ethylcellulose was considered to be the most suitable product.
    TABLE II
    Characteristics of products tested
    Solubility
    in
    ethanol
    Products Cold Hot Visual examination
    Hydroxypropylcellulose − + After cooling, non-
    − + homogeneous
    Ethylcellulose ± + Clear gel
    Polysorbate − + Very low viscosity
    Colloidal Silica − + Only becomes viscous a
    − + few days later
    Carboxypolymethylene − + Precipitates after
    − + neutralisation
    Polyethyleneglycol − + Precipitates on cooling
    − +
    • Manufacture of the Preparation
  • Several preparations at different ethylcellulose concentrations were made up by dissolving 0.15, 0.45 and 0.75 g in 15 mL of ethanol with a purity of 70 to 99% by volume and preferably 95% (d=0.8), that is 1.22, 3.61 and 5.88% by weight of the preparation's total weight.
  • The preparation with the highest ethylcellulose concentration was chosen. A loss of 2.5% on distribution into bottles was observed, that is proportions of 205 mL of 950 alcohol (% volume) and 10.25 g of ethylcellulose per forty bottles.*
  • More generally, ethylcellulose is used at a concentration ranging from 0.5 to 15%, preferably 5.88%, by weight of the preparation's total weight.
  • In accordance with Good Manufacturing Practice (1998), the preparation was manufactured in three stages: gel preparation, aseptic distribution and sterilisation of the product in the final packaging. To start with, the excipient (ethylcellulose) was mixed by magnetic stirring with hot ethanol in a sterile ground-glass neck flask and refluxed until completely dissolved. The mixture was stirred and refluxed for 15 minutes then stirred until it cooled down completely in order to allow recondensation of the alcohol in the flask. It was then packaged under a horizontal laminar flux hood into 5 mL sterile bottles (bioblock 42065). Finally, in accordance with European Pharmacopoeia recommendations, the bottles were sterilised in a autoclave using saturated vapour at 121° C. for 20 minutes.
  • The final step in the manufacturing process of the preparation is the addition of a powdered opacifying compound such as tantalum oxide or tungsten oxide in varying proportions so as to obtain good opacity. This addition can take place either at the end of the manufacturing process prior to packaging or just before carrying out the injection.
  • As these compounds are inert and used in very small amounts, they do not significantly alter the results of the tests described below and carried out on the preparation prior to their addition.
    • Tested Carried Out
  • The conformity of the preparation was verified by means of a sterility test and chemical and physico-chemical tests.
  • In accordance with European Pharmacopoeia recommendations, the possible presence of any contaminants was investigated by culturing 4 mL of the preparation in 250 mL of tryticase-soya broth for aerobic germs, thioglycate for anaerobic germs and Sabouraud for yeasts. The results of the sterility test confirmed the absence of any contaminants in the preparation.
  • Alcohol content was determined after dilution of a sample and incorporation of the internal standard, propanol-1, by gas chromatography with detection by flame ionisation. Separation was by means of a Porapak Q column (80-100 mesh, length 3 m) with nitrogen as the carrier gas (1.2 bar) on a Delsi DN200 apparatus. The alcohol assay gave a value of 802 g.L−1.
  • The specific assay for the viscosity additive was not performed but the concentration was estimated by means of the dry residues method, a process which consists in evaporating ethanol in a tank whose temperature was maintained at 110° C. until the sample reached constant weight.
  • The dry residues method allowed a correlation to be made between the theoretical ethylcellulose concentration and the experimentally measured concentration, that is 5.88% by weight of the sample's total weight.
  • The viscosity of the preparation was measured by means of a Baumé capillary viscosimeter (Prolabo). Several series of measurements were performed at different temperatures and different concentrations of the thickener. The viscosity measurements showed that, at constant temperature, the preparation increased exponentially as a function of ethylcellulose content (FIG. 1). However, it decreased, also exponentially, when the temperature increased (FIG. 2).
  • Finally, the physico-chemical stability study was carried out by means of analysis as a function of time of the changes in the parameters defining the preparation, on other words viscosity, ethanol content and viscosity agent. The measurements were repeated on day 1 (D1), day eight (D8), day fifteen (D15) and day thirty (D30). The results are given in Table III. The coefficients of variation, below 3%, prove that the mixture is stable up to D30, which will allow an expiry date for the preparation to be determined.
    TABLE III
    Physico-chemical parameters as a function of time
    Cethanol Dry DR/Wech
    (g · Wech Dech residue ratio Viscosity
    Date L−1) Véch (mL) (g) (g · mL−1) DR (g) (%) (cp)*
    D1 784 2 1.650 0.825 0.101 6.10 320
    D8 821 2 1.720 0.850 0.103 5.97 339.5
    D15 783 2 1.610 0.800 0.097 6.00 —
    D30 820 2 1.670 0.830 0.099 5.92 332
    Mean 802 — 1.663 0.826 0.100 5.998 330.5
    Standard 21.370 — 0.046 0.021 0.002 0.076 9.836
    deviation
    Coefficient 2.665 — 2.751 2.489 2.458 1.265 2.976
    of
    variation

    *cp: pharmaceutical unit
  • Injection of the preparation into the lumbar disc led to decreased intra-discal pressure and, therefore, to reduced back pain caused by discal hernias.

Claims (7)

1. Viscous injectable preparation, comprising at least one compound to give a viscous preparation, ethanol and at least one compound to make said preparation opaque to X-rays, said compound used to give a viscous preparation soluble in cold ethanol.
2. Preparation according to claim 1, wherein said compound used to give a viscous preparation is ethylcellulose.
3. Preparation according to claim 2, wherein ethylcellulose is used at a concentration ranging from 0.5 to 15%, preferably 5.88%, by weight of the preparation's total weight.
4. Preparation according to claim 1, wherein said compound making said preparation opaque to X-rays is an inert compound.
5. Preparation according to claim 4, wherein said compound making said preparation opaque to X-rays is tantalum oxide.
6. Preparation according to claim 4, wherein said compound making said preparation opaque to X-rays is tungsten oxide.
7. Preparation according to claim 1, wherein said ethanol has a purity of 70 to 99% by volume, preferably 95%.
US10/513,592 2002-05-07 2003-05-07 Medicinal preparation particularly for the treatment of slipped discs hernias Abandoned US20070116647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0205819A FR2839450B1 (en) 2002-05-07 2002-05-07 MEDICAMENT PREPARATION IN PARTICULAR FOR THE TREATMENT OF HERNIES DISCALES
FR02/05819 2002-05-07
PCT/FR2003/001412 WO2003097108A1 (en) 2002-05-07 2003-05-07 Medicinal formulation in particular for treating herniated invertebral discs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001412 A-371-Of-International WO2003097108A1 (en) 2002-05-07 2003-05-07 Medicinal formulation in particular for treating herniated invertebral discs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/870,258 Division US8153696B2 (en) 2002-05-07 2010-08-27 Medicinal preparation particularly for the treatment of slipped discs hernias

Publications (1)

Publication Number Publication Date
US20070116647A1 true US20070116647A1 (en) 2007-05-24

Family

ID=29286406

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/513,592 Abandoned US20070116647A1 (en) 2002-05-07 2003-05-07 Medicinal preparation particularly for the treatment of slipped discs hernias
US12/870,258 Expired - Fee Related US8153696B2 (en) 2002-05-07 2010-08-27 Medicinal preparation particularly for the treatment of slipped discs hernias
US13/681,175 Abandoned US20130143970A1 (en) 2002-05-07 2012-11-19 Medicinal preparation particularly for the treatment of slipped discs hernias

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/870,258 Expired - Fee Related US8153696B2 (en) 2002-05-07 2010-08-27 Medicinal preparation particularly for the treatment of slipped discs hernias
US13/681,175 Abandoned US20130143970A1 (en) 2002-05-07 2012-11-19 Medicinal preparation particularly for the treatment of slipped discs hernias

Country Status (15)

Country Link
US (3) US20070116647A1 (en)
EP (1) EP1503803B1 (en)
CN (1) CN100402020C (en)
AT (1) ATE402719T1 (en)
AU (1) AU2003262617A1 (en)
CA (1) CA2498976C (en)
CY (1) CY1108413T1 (en)
DE (1) DE60322530D1 (en)
DK (1) DK1503803T3 (en)
ES (1) ES2309334T3 (en)
FR (1) FR2839450B1 (en)
HK (1) HK1081849A1 (en)
PT (1) PT1503803E (en)
SI (1) SI1503803T1 (en)
WO (1) WO2003097108A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2839450B1 (en) * 2002-05-07 2006-04-07 Aboville Marc D MEDICAMENT PREPARATION IN PARTICULAR FOR THE TREATMENT OF HERNIES DISCALES
FR2891461B1 (en) * 2005-09-30 2010-09-03 Jacques Theron INJECTABLE VISCOUS MEDICINAL PREPARATION COMPRISING ETHANOL AND X-RAY OPAQUE LIPOSOLUBLE COMPOUND
CA3075219A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Hnf4a sarna compositions and methods of use
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
CA3151996A1 (en) 2019-08-19 2021-02-25 Mina Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
CN117222405A (en) * 2021-03-04 2023-12-12 苏州医本生命科技有限公司 Ethanol-containing pharmaceutical composition and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2162028A (en) * 1938-06-25 1939-06-13 Pittsburgh Plate Glass Co Cellulose ether coating composition
US2903396A (en) * 1957-05-08 1959-09-08 Ciba Pharm Prod Inc Therapeutic compositions and method for treating parkinsonism
US5177056A (en) * 1987-08-21 1993-01-05 Ciba-Geigy Corporation Plastics composition containing superconductors
US5830178A (en) * 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6150022A (en) * 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US20020115904A1 (en) * 2001-02-21 2002-08-22 Brooke Ren Magnetically controllable embolic materials
US6476070B2 (en) * 1997-09-11 2002-11-05 Provasis Therapeutics Inc. Compositions useful for remodeling body spaces

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02157029A (en) * 1988-12-09 1990-06-15 Dainippon Pharmaceut Co Ltd Stabilization of composition containing anionic surfactant
JP2003502131A (en) * 1999-05-21 2003-01-21 マイクロ・セラピューティクス・インコーポレーテッド Method for embolizing a vascular site using an embolizing composition
EP1987847A1 (en) * 1999-05-21 2008-11-05 Micro Therapeutics, Inc. Novel high viscosity embolizing compositions
US6355058B1 (en) * 1999-12-30 2002-03-12 Advanced Cardiovascular Systems, Inc. Stent with radiopaque coating consisting of particles in a binder
FR2839450B1 (en) * 2002-05-07 2006-04-07 Aboville Marc D MEDICAMENT PREPARATION IN PARTICULAR FOR THE TREATMENT OF HERNIES DISCALES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2162028A (en) * 1938-06-25 1939-06-13 Pittsburgh Plate Glass Co Cellulose ether coating composition
US2903396A (en) * 1957-05-08 1959-09-08 Ciba Pharm Prod Inc Therapeutic compositions and method for treating parkinsonism
US5177056A (en) * 1987-08-21 1993-01-05 Ciba-Geigy Corporation Plastics composition containing superconductors
US5830178A (en) * 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US6476070B2 (en) * 1997-09-11 2002-11-05 Provasis Therapeutics Inc. Compositions useful for remodeling body spaces
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6150022A (en) * 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US20020115904A1 (en) * 2001-02-21 2002-08-22 Brooke Ren Magnetically controllable embolic materials

Also Published As

Publication number Publication date
ATE402719T1 (en) 2008-08-15
CA2498976A1 (en) 2003-11-27
WO2003097108A1 (en) 2003-11-27
CN1665546A (en) 2005-09-07
FR2839450B1 (en) 2006-04-07
ES2309334T3 (en) 2008-12-16
FR2839450A1 (en) 2003-11-14
AU2003262617A1 (en) 2003-12-02
PT1503803E (en) 2008-10-16
SI1503803T1 (en) 2008-12-31
EP1503803A1 (en) 2005-02-09
US20130143970A1 (en) 2013-06-06
HK1081849A1 (en) 2006-05-26
US8153696B2 (en) 2012-04-10
EP1503803B1 (en) 2008-07-30
CA2498976C (en) 2011-09-06
DE60322530D1 (en) 2008-09-11
US20100329991A1 (en) 2010-12-30
CY1108413T1 (en) 2014-02-12
CN100402020C (en) 2008-07-16
DK1503803T3 (en) 2008-11-10

Similar Documents

Publication Publication Date Title
US8153696B2 (en) Medicinal preparation particularly for the treatment of slipped discs hernias
US9254263B2 (en) Thermogelling anaesthetic compositions
JPH07149624A (en) Rapamycin preparation for intravenous injection
JP6356873B2 (en) Taxane active ingredient-containing liquid composition and liquid formulation
RU2564001C2 (en) Therapeutic medication against spinal disc herniation
Sesay et al. Intraosseous lidocaine provides effective analgesia for percutaneous vertebroplasty of osteoporotic fractures
TW570795B (en) Pharmaceutical compositions containing phospholipase inhibitor
TWI772659B (en) Pharmaceutical formulation
CN112823787B (en) Injection containing meloxicam and preparation method thereof
JPH064534B2 (en) Combination drug for long-term pain relief
TWI244922B (en) OCT preparation with 1alpha,25-dihydroxy-22-oxavitamin D3 (OCT)
JP3584064B2 (en) Rapamycin formulation for intravenous injection
US20230038716A1 (en) Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes
RU2442569C2 (en) Viscous medical product for injections, containing ethanol and fat-soluble, impenetrable connection for x-ray radiation
JP2024512704A (en) local anesthetic emulsion
JPH05271075A (en) Anti-inflammatory analgesic cream preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: THERON, JACQUES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:D'ABOVILLE, CHRISTINE MARIE JOSEPH (ON BEHALF OF MARC D'ABOVILLE (DECEASED);D'ABOVILLE, SOLINE ALIX MARIE (ON BEHALF OF MARC D'ABOVILLE, DECEASED);D'ABOVILLE, COME PHILIPPE GUY (ON BEHALF OF MARC D'ABOVILLE, DECEASED);AND OTHERS;REEL/FRAME:019774/0203;SIGNING DATES FROM 20050625 TO 20050725

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION